Characteristics of Type 2 Diabetes Patients, Treated With Insulin and Their Follow up Care in Guadeloupe

Overview

Type 2 diabetes is a major problem of public health in the French West Indies, with an estimated prevalence of 8%, twice more than in France. In Guadeloupe, according to the statistical data of hospital morbidity in 2004, 2643 hospital stays were diagnosed with diabetes. These cases mainly concerned woman (62%) and the elderly, from 45 to 74 years old (67%). The main objective of this research is to describe the insulin protocol used in Guadeloupe for treated type 2 diabetes patients and their characteristics: – The duration of the type 2 diabetes – Time elapsing between the diagnosis and the treatment by insulin – Where the follow up care took place – Existence of complications Secondary objectives were to describe the link between the HbA1c rate and the insulin therapy protocol. And also to present the main inconveniences expressed by patients and their degree of autonomy.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: September 27, 2016

Detailed Description

Nowadays the set up for insulin treatment is available in general practitioners' offices. However, it is restrained by the reticence of patients and physicians. For type 2 diabetes, insulin therapy is well managed and there is ongoing progress. But there are still some questions about the effect of the treatment in the everyday life of patients: culture, fear, material resources, necessity of education. Ignorance and prejudices on insulin injection are still prevalent and often it delays for more than a year the time when patients have to switch an insulin treatment for unbalanced chronic disorder. Type 2 diabetes patients think that the treatment is heavy, can lead to serious hypoglycemia, is uncomfortable for family and can cause fear. Education of the patients can reduce ignorance and prejudices about insulin treatment. Nowadays studies show that diabetes patients want to be more involved in the decisions linked to their treatment which impact their perception of the disease and the treatment. Auto measurement of glycaemia can help the patient better manage his disease and make him understand the importance of controlling his glycaemia levels. This study could allow to: – Offer a new care organization for a better use of resources (network, patient therapeutic education…) – Set up adequate training for professionals and for patients being cared for in medical offices. – Improve the glycemic balance of patients and slower the growth of degenerative complications.

Interventions

  • Other: Description of plans insuliniques used in Guadeloupe in the type 2 diabetes and the characteristics of the handled patients:
    • The physician or the endocrinologist will see the patient during his consultation. The pharmacist will see the patient when he goes to the pharmacy for an insulin treatment. In each case, the patient will be informed about the study, about the medical data that will be collected anonymously. The date will be strictly confidential and under medical secrecy. Then the patient will meet the physician during another consultation at the University Hospital Center of Guadeloupe, in order to collect information’s on a questionnaire. Otherwise, the physician can meet the patient at his home, in case he can’t move to the University Hospital Center of Guadeloupe.

Clinical Trial Outcome Measures

Primary Measures

  • Characteristic of type 2 diabetes patients, treated with insulin in Guadeloupe
    • Time Frame: Trough study completion, an average of 2 years
    • A descriptive analysis will be done on the population concerned by the study, for the socio demographic, clinical and therapeutic characteristics. the duration of the type 2 diabetes, time elapsing between the diagnostic and the treatment by insulin, place of the follow up care, existence of complications.

Secondary Measures

  • Describe the relation between the rate of HbAC and the plan of insulinothérapie
    • Time Frame: Trough study completion, an average of 2 years
    • Sreening of HbAC

Participating in This Clinical Trial

Inclusion Criteria

  • Men or woman – Age ≥ 18 years old – Patient with type 2 diabetes, treated with insulin for at least one year – Patient accepting to participate to the study Exclusion Criteria:

• Pregnant or breastfeeding woman

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Centre Hospitalier Universitaire de Pointe-a-Pitre
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Pauline NOUVIER KANGAMBEGA, medicine degree, diabetes, Principal Investigator, Hospital University Center of Pointe-à-Pitre

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.